Celyad Oncology (1C0) Stock Overview
A biotechnology company, focuses on unlocking the potential of its intellectual property. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1C0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.19 |
| 52 Week High | €0.46 |
| 52 Week Low | €0.13 |
| Beta | 1.21 |
| 1 Month Change | -33.80% |
| 3 Month Change | -48.35% |
| 1 Year Change | -40.51% |
| 3 Year Change | -62.70% |
| 5 Year Change | -95.01% |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1C0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | -0.5% | 2.0% |
| 1Y | -40.5% | 17.0% | 1.2% |
Return vs Industry: 1C0 underperformed the German Biotechs industry which returned 17% over the past year.
Return vs Market: 1C0 underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| 1C0 volatility | |
|---|---|
| 1C0 Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 1C0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1C0's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | n/a | celyad.com |
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020.
Celyad Oncology SA Fundamentals Summary
| 1C0 fundamental statistics | |
|---|---|
| Market cap | €10.43m |
| Earnings (TTM) | €830.00k |
| Revenue (TTM) | €21.00k |
Is 1C0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1C0 income statement (TTM) | |
|---|---|
| Revenue | €21.00k |
| Cost of Revenue | €8.00k |
| Gross Profit | €13.00k |
| Other Expenses | -€817.00k |
| Earnings | €830.00k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 23, 2026
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 61.90% |
| Net Profit Margin | 3,952.38% |
| Debt/Equity Ratio | 0% |
How did 1C0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 00:11 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celyad Oncology SA is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Edward White | H.C. Wainwright & Co. |
| Guy Sips | KBC Securities NV |